Raymond James & Associates Raises Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Raymond James & Associates grew its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 32.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 21,362 shares of the company’s stock after buying an additional 5,229 shares during the period. Raymond James & Associates’ holdings in Maravai LifeSciences were worth $266,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of MRVI. Zions Bancorporation N.A. purchased a new position in Maravai LifeSciences in the first quarter worth about $28,000. Meeder Asset Management Inc. purchased a new position in Maravai LifeSciences in the first quarter worth about $31,000. Jefferies Financial Group Inc. purchased a new position in Maravai LifeSciences in the fourth quarter worth about $45,000. Harbor Capital Advisors Inc. purchased a new position in Maravai LifeSciences in the second quarter worth about $47,000. Finally, Lazard Asset Management LLC raised its holdings in Maravai LifeSciences by 8,207.5% in the fourth quarter. Lazard Asset Management LLC now owns 3,323 shares of the company’s stock worth $47,000 after buying an additional 3,283 shares during the last quarter. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Stock Performance

Shares of NASDAQ MRVI opened at $5.13 on Friday. The firm has a 50 day moving average of $8.47 and a 200 day moving average of $11.02. The company has a current ratio of 8.96, a quick ratio of 8.70 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of 28.50 and a beta of -0.11. Maravai LifeSciences Holdings, Inc. has a 12-month low of $4.52 and a 12-month high of $16.90.

Wall Street Analysts Forecast Growth

MRVI has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Maravai LifeSciences from $23.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, August 8th. The Goldman Sachs Group reduced their price target on shares of Maravai LifeSciences from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Thursday. KeyCorp lowered shares of Maravai LifeSciences from an “overweight” rating to a “sector weight” rating in a research note on Tuesday, August 8th. Credit Suisse Group reduced their price target on shares of Maravai LifeSciences from $14.00 to $11.00 and set a “neutral” rating for the company in a research note on Tuesday, August 8th. Finally, Morgan Stanley reduced their price target on shares of Maravai LifeSciences from $12.00 to $11.00 and set an “overweight” rating for the company in a research note on Thursday. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $13.90.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.